Our Programs

CRISPR-based drug candidates for difficult-to-treat infections.

CRISPR-based drug candidates for precision microbiome engineering in auto-immune & malignant disorders.

CRISPR Technology

SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively eradicate target bacteria, while leaving the rest of the patient’s microbial community intact.

We are utilizing the bacteria’s adaptive CRISPR-based immune system in a fully programmable fashion to very selectively kill target bacteria based on specific DNA sequence signatures in the bacterial genome.

Medical Focus

SNIPR BIOME has the potential to develop valuable therapeutics within multiple important disease areas, and we have decided to focus initially on novel, narrow-spectrum (or otherwise rationally-tailored) anti-bacterial drug candidates for use in difficult-to-treat infections or precision microbiome modulation for the auto-immunity and oncology/immuno-oncology setting.

CRISPR-based medicines hold the promise to offer very safe medications due to their very high specificity.